Navigation Links
Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
Date:11/24/2009

SAN DIEGO, Nov. 24 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the 21st Annual Piper Jaffray Health Care Conference in New York.

The live presentation takes place Tuesday, December 1, 2009 at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT). The presentation will be simultaneously webcast and may be accessed on the Company's website at http://www.neurocrine.com.

If you are unable to attend the webcast and would like further information on this announcement please contact Investor Relations at Neurocrine Biosciences at (858) 617-7600. Viewers are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software. A replay of the presentation will be available approximately one hour after the conclusion of the live event and will be archived on the website for two weeks.

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on neurological and endocrine diseases and disorders. Our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, anxiety, depression, pain, diabetes, benign prostatic hyperplasia (BPH), irritable bowel syndrome (IBS) and other neurological and endocrine related diseases and disorders. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the internet at http://www.neurocrine.com.

SOURCE Neurocrine Biosciences, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Neurocrine Biosciences Reports Third Quarter 2009 Results
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
3. Neurocrine Biosciences Presents Elagolix Data
4. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
5. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
6. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
9. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
10. Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results
11. Cell Biosciences Completes Acquisition of Alpha Innotech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Inc. (NYSE: RMD ) today announced results for ... 30, 2014.  Revenue for the quarter was $415.2 million, flat ... percent decrease on a constant currency basis). Net income was ... quarter ended June 30, 2013. Diluted earnings per share for ... to the quarter ended June 30, 2013.  ...
(Date:7/31/2014)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. Wedbush Life ... Wednesday, August 13, 2014 at 9.10 a.m. Eastern Time ... York, NY Thursday, September 4, 2014 at 8.30 ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:7/31/2014)... 31, 2014  UBM Medica US announces that ... for oncologists, presents exclusive slide shows dealing with communication ... quality cancer care. Cancer Network, ... offers news, blogs, and podcasts about the latest clinical ... care: , End-of-life care is challenging for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Cepheid to Webcast Upcoming Financial Presentations 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3
... , NEW YORK, Dec. 7 ... updated efficacy and safety data as well as new ... in combination with bortezomib (Velcade(R)) (+/- dexamethasone) in patients ... "A Multicenter Phase 1/2 Study Evaluating the Safety and ...
... , ENGLEWOOD, Colo., Dec. 7 ... system, DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting ... patient safety and pharmacy efficiency through the management of ... easily into current pharmacy practice and techniques, while providing ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3
(Date:8/1/2014)... York, New York (PRWEB) August 01, 2014 ... http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly experienced ... of power morcellators in gynecological surgeries, Bernstein Liebhard LLP ... to withdraw a number of power morcellators marketed by ... a report from The New York Times, some critics ...
(Date:8/1/2014)... benefits of a cancer diagnosis may improve health outcomes ... conducted by a researcher at the University of Houston ... writing intervention is the writing instruction. Otherwise, writing is ... a journal can be therapeutic, but oftentimes we don,t ... or not," said Qian Lu, assistant professor and director ...
(Date:8/1/2014)... August 01, 2014 On Monday, June ... NextGen User Symposium in San Francisco, CA. Now in ... the JW Marriott Union Square hotel. , “We are ... up to speed with ACA compliance issues,” Quirk Healthcare ... The symposium provides attendees guidance with NextGen implementation and ...
(Date:8/1/2014)... August 01, 2014 According to ... by Geography (Asia-Pacific, North America, Europe, & ROW), ... by Fuel Type (Gasoline & Diesel), by After-Treatment ... - Trends & Forecasts to 2019", defines and ... an analysis of major countries in all the ...
(Date:8/1/2014)... Scientists at Albert Einstein College of Medicine ... aid in digestion help keep the intestinal lining intact. ... , could yield new therapies for inflammatory bowel disease ... The research involved the intestinal microbiome, which contains some ... promoting or preventing disease is a major emerging field ...
Breaking Medicine News(10 mins):Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Exhaust Systems Market Will Be $33,379.7 Million by 2019 – New Report by MarketsandMarkets 4Health News:'Normal' bacteria vital for keeping intestinal lining intact 2
... scientists implicates a new protein in obesity development and highlights ... resistance. Jorge Moscat, PhD, chair of UC,s ... ERK are involved in adipogeneis, (the development of adipocytes, or ... works together. The study is published online in ...
... , BOULDER, Colo. , ... of Functional Fitness on Walk the Talk ... Sam Iannetta , a champion powerlifter, tells—and shows—how ... healing injuries, whatever your fitness practice: yoga, cycling, ...
... SHANGHAI , Feb. 12 General Nutrition ... announced today that it, together with its parent company, has entered ... Bright Food (Group) Co., LTD (Bright Food). The partnership, to be ... market. Bright Food , a leading state-owned conglomerate in ...
... received male donors, plasma had worse outcomes, study found ... blood-banking industry discourages transfusing the blood product known as ... reaction in the recipients. , But now researchers have ... have advantages. , Plasma is the fluid in ...
... Touching down toe-first is less economical in humans, research shows , ... to walk heel-first than to walk on the balls of your ... Compared with heel-first walking, it takes 83 percent more energy to ... on the balls of your feet, according to the University of ...
... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ... ... has just released their emWave® Desktop product. emWave Desktop works on both PC and ...
Cached Medicine News:Health News:Research highlights role of protein pair in obesity regulation 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Restrictions on Plasma From Female Donors May Need Revisiting 2Health News:Heel-First Walking Conserves Energy 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 2Health News:HeartMath Announces the Release of Their New emWave Desktop Software 3Health News:HeartMath Announces the Release of Their New emWave Desktop Software 4
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: